5 September 2025 - Takeda today announced that the US FDA has approved the supplemental biologics license application for Vonvendi [von Willebrand factor (recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand disease, including those with type 1 and 2 disease, and on-demand and peri-operative management of bleeding in paediatric patients with von Willebrand disease. 

Vonvendi was previously approved for on-demand and peri-operative use in adults with von Willebrand disease and routine prophylactic use in adults with severe type 3 von Willebrand disease receiving on-demand therapy.

Read Takeda press release